On July 21, the annual 2021 Mis Conference kicked off at the Yunnan Kunming Yun'an Huidu International Convention Center. The highly anticipated highlight, the 2020 Top 100 Chinese Pharmaceutical Industry List, was grandly unveiled!
Health Yuan Group, with its solid R&D and production capabilities and excellent market development capabilities, successfully entered the "2020 Top 100 Chinese Pharmaceutical Industry List" sub-list, "2019 Top 100 Chinese Chemical Pharmaceutical Enterprises Ranking", ranking among the top nine nationwide!
It is understood that the Mi Nei Research Institute organized the Expert Committee of the Top 100 Chinese Pharmaceutical Industry Ranking. Relying on the three major terminal and six major market terminal pattern databases that Mi Nei.com has exclusively developed and operated in China for many years, targeting pharmaceutical companies, from the two most important dimensions of innovation driving force and professional promotion capabilities, the "2020 Top 100 Chinese Pharmaceutical Industry List" was selected, which is highly authoritative in the industry.
The total score of the selected companies consists of two parts: one is the company's innovation driving force, namely the 2020 R&D investment R&D comprehensive index score, accounting for 40% of the weight; the other is the company's professional promotion capability, namely the terminal quantitative data determined by the ultimate choice needs of clinical doctors and patients in 2020, which is rigidly defined, that is, the score obtained by quantitative analysis combining Mi Nei.com's exclusive three major terminal and six major market terminal data, accounting for 60% of the weight. The companies selected for this list are all benchmarks and role models in the Chinese pharmaceutical industry, and this honor is an important recognition of their persistence and dedication.
The "2020 Top 100 Chinese Pharmaceutical Industry List" is divided into five sub-lists: "Top 100 Chinese Chemical Pharmaceutical Enterprises Ranking", "Top 100 Chinese Traditional Chinese Medicine Enterprises Ranking", "Top 20 Chinese CRO (including CDMO) Enterprises Ranking", "Top 20 Chinese Medical Devices (including IVD) Enterprises Ranking", and "Top 20 Chinese Biopharmaceutical (including blood products, vaccines, insulin, etc.) Enterprises Ranking", with a total of 260 companies on the list.
Health Yuan, which successfully entered the top nine nationwide in the 2020 Top 100 Chinese Chemical Pharmaceutical Enterprises Ranking, has been deeply involved in the great health field for many years, always adhering to innovation-driven development, and has strong R&D capabilities and international R&D concepts in the fields of chemical and traditional Chinese medicine preparations, biological drugs, diagnostic reagents, and health products.
Based on its existing advantages, Health Yuan focuses on innovative drugs and high-barrier complex preparations, focusing on the development of four major R&D platforms: monoclonal antibodies, inhalation preparations, lipid microemulsions, and sustained-release microspheres platforms, continuously strengthening the innovative R&D and business layout of respiratory, mental, and tumor immunity products. Among them, the layout in the inhalation preparation sector is relatively leading. After gradually entering the product harvest period, many inhalation preparations have been approved for listing, and three major inhalation preparation products have been selected into the fifth batch of national drug centralized procurement list, successfully proving the strong R&D strength of domestic inhalation preparations replacing imported original research drugs. This has enabled Health Yuan to gradually gain a foothold in the domestic inhalation preparation field, obtaining more market opportunities and development space for the company's current and future development.
Looking back at 2020, the sudden COVID-19 epidemic has affected people's lives and also put forward higher new requirements for pharmaceutical companies. Under the general environment of frequent new pharmaceutical policies, industry concentration, and the rapid development of pharmaceutical e-commerce, the release of this list is undoubtedly one of the most important events of this year, and it is also an important measure to further enhance consumers' understanding of excellent enterprises in the pharmaceutical industry. This honor is an authoritative recognition of Health Yuan's comprehensive strength and future growth potential by society and the industry.
Looking to the future, Health Yuan will always maintain its pharmaceutical aspirations, with the mission of "For Health, For Tomorrow", the vision of "Making Good Medicines and New Medicines with Care", and the core values of "People-Oriented, Craftsmanship Quality, Innovation and Pragmatism, Cooperation and Sharing", continuously focusing on patients' medication needs, and striving to grow into an innovative pharmaceutical enterprise with industry influence under the dual drive of innovation and high-barrier technology platforms!
